To Whom It May Concern,

Company Name: Taisho Pharmaceutical Holdings Co., Ltd.

Head Office: 3-24-1, Takada, Toshima-ku, Tokyo Representative: Akira Uehara, Chief Executive Officer

(TSE Standard Market: Code 4581)

Contact: Shinichi Tanaka, General Manager

Corporate Communications (Tel: +81-3-3985-2020)

Notice Concerning Determination of Details of Stock Options (Stock Acquisition Rights)

Taisho Pharmaceutical Holdings Co., Ltd. ("the Company") announced that it has finalized the following matters regarding the issuance of stock options (subscription rights) announced on June 29, 2023, which had not been determined at the time. The Company resolved at its board of directors meeting held on June 29, 2023, to issue stock acquisition rights as stock options (Name: Taisho Pharmaceutical Holdings Co., Ltd. 12th Series of Stock Acquisition Rights) to the members of the board and other officers of the Company, along with the members of the board and other officers of Taisho Pharmaceutical Co., Ltd., a subsidiary of the Company.

(1)	Total number of stock acquisition rights	The total number of stock acquisition rights shall be 139. (The number of shares for each stock acquisition right shall be 100.)
(2)	Stock acquisition right allotment recipients, number of recipients, and the number of stock acquisition rights to be allotted	Members of the board of the Company (excluding outside directors) 6 individuals 38 stock acquisition rights Corporate officer of the Company 2 individuals 2 stock acquisition rights Members of the board of Taisho Pharmaceutical Co., Ltd. 8 individuals 52 stock acquisition rights Other officers of Taisho Pharmaceutical Co., Ltd. 19 individuals 47 stock acquisition rights
(3)	Amount to be paid per stock acquisition right	Amount to be paid per stock acquisition right: 566,000 yen (Amount per share: 5,660yen) (The Company shall offset the amount to be paid for the stock acquisition rights with compensation claimable from the Company by stock acquisition right allotment recipients.)